ClinicalTrials.gg
CompletedNCT07446881B06Updated Mar 10, 2026

A Phase 1 Study, to Evaluate the Effect of ADV7103 on Gastric pH Under Fed and Fasting Conditions in Adult Healthy Participants.

A Phase 1 interventional study of ADV7103 in EFFECT OF ADV7103 ON GASTRIC PH and Distal Renal Tublular Acidosis, sponsored by Advicenne Pharma. Completed at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Advicenne Pharma · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Feb 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Acidosis with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Acidosis · France.

Started
2025
with 1 other
Phase 1
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
1 of 12
Advicenne Pharma

Among the 12 studies in Acidosis with a site in France, this one is one of 2 that started in 2025, is the only one in phase 1, and was the 12th registered.

Acidosis

111 studies on the registry are indexed under Acidosis; 19 are open to participants now.

Browse Acidosis studies →

Open to participants now

4 of the 12 studies in Acidosis with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 17 Acidosis studies recruiting now, 13 (76%) set no upper age limit and 2 (12%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Acidosis with a site in France, or all of them as a file.
02

Study summary

This was a Phase 1, single-center, randomized, controlled, Latin-square, open-label study to evaluate the effect of ADV7103 on the gastric pH, after administering a single oral dose of ADV7103 in healthy adult participants under fasting and fed conditions

03

Conditions studied

  • EFFECT OF ADV7103 ON GASTRIC PH
  • Distal Renal Tublular Acidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Healthy male or female, who were aged 18-45 years (inclusive) on the day of signing the form (ICF).

4. Had a body weight between 50.0-100.0 kg (inclusive) at screening and D-1. 5. Had a (BMI) between 18.0-30.0 kg/m2 (inclusive) at screening and D-1.

Participants had vital signs results within normal ranges at screening and D-1. If outside normal ranges, the values were considered by the Investigator without abnormal findings. 7. Had physical examination results without clinically significant abnormal findings confirmed by the Investigator at screening and D-1. 8. Had clinical laboratory test results (hematology, coagulation, blood chemistry and urinalysis) within normal ranges at screening. If outside of normal ranges, the values were considered by the Investigator as not clinically significant, without abnormal findings.

9. Had 12-lead results without clinically significant abnormal findings confirmed by the Investigator at screening.

Female participants who were not pregnant confirmed by beta-human chorionic gonadotropin (β-HCG) or nursing at screening and D-1, or who were not planning to become pregnant during study period.

11. Female participants of non-, defined as one of the following:

  1. At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., appropriate age) and follicle-stimulating hormone (FSH) in the range for menopausal female confirmed by blood test according to current local standards at screening, except if treated with hormone replacement therapy (HRT]).
  2. Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening.

    12. Female participants of childbearing potential (WOCBP) agreed to use an adequate and highly effective method of (according to Clinical Trials Coordination Group [CTCG] recommendations) starting at screening and throughout the entire study: a) Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, started at least 4 weeks prior to the dosing (D1) and use of condom for the male partner.

b) Progestogen-only hormonal contraception associated with inhibition of ovulation, started at least 4 weeks prior to the dosing (D1) and use of condom for the male partner.

c) Intrauterine device (IUD) placed at least 4 weeks prior to the dosing (D1), and use of condom for the male partner.

d) Intrauterine hormone-releasing system (IUS) placed at least 4 weeks prior to the dosing (D1), and use of condom for the male partner.

e) Simultaneous use of a diaphragm or cervical cap with intravaginally applied spermicide and, for the male partner, a male condom. f) Sterile male partner, i.e., vasectomized since at least 3 months before inclusion.

Sexual abstinence[4] (when in line with the preferred and usual participant's lifestyle). Note: Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception. 13. Male participants were either surgically sterile (> 90 days since vasectomy), or abstinent as a usual practice, or if engaged in sexual relations with a WOCBP, the participant and his partner were either surgically sterile or used an acceptable, highly effective contraceptive method according to CTCG recommendations starting at screening and throughout the entire study.

14. Male participants agreed to abstain from sperm donation starting at screening and throughout the trial. Regulations 15. Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.

16. Was competent in speaking, writing, and comprehending the local language(s) where the study is conducted.

Exclusion criteria

Exclusion Criteria:

Had a history of and/or current , determined by the Investigator, gastrointestinal, renal, hepatic, cardiovascular, hematological, respiratory, neurologic, metabolic, psychiatric, infectious disorder, drug or alcohol abuse, or allergic disease, , or allergic reactions excluding mild asymptomatic seasonal allergies (either spontaneous or following drug administration).

2. Had a history of (including lymphoma, leukemia, and skin cancer) unless remission at least 10 years prior to screening.

3. Had a history of metabolic alkalosis or hyperkalemia. 4. Had urinary infection. 5. Had a history of difficult access to the oral administration route and/or conditions that could have hampered compliance and/or absorption of the IMPs, and/or the use and/or the proper functioning of the pH probe (e.g., gastroesophageal reflux, gastrectomy, bariatric surgery).

6. Had a personal or family history of prolonged syndrome or Torsade de Pointes, or family history of sudden death.

7. Had surgery (including invasive dental treatment or dental surgery) within one month or considered clinically significant by the Investigator, prior to D1, and/or planned to have surgery over the course of the study.

8. Had a history and/or current presence of an illness within 14 days prior to D1 that was categorized as clinically significant by the Investigator. Had history or presence of regular use of recreational drugs within 1 year before screening. 10. Donated blood or had blood loss (i.e., > 450 mL) within 1 month before screening.

11. Had known allergies, hypersensitivity or intolerance to IMP, or present in drug product.

Physical and Laboratory Findings 12. Individualized estimated (eGFR): [(standard CKD-EPI÷1.73)×BSA] \<90 mL/min. at screening. 13. Had a positive pregnancy test for female participants. 14. Had a positive test result for surface antigen (HBsAg), virus (HCV) antibody, or (HIV) 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab) at screening.

15. Had positive findings of urine drug screen (methadone, barbiturates, morphine, amphetamines, methamphetamines, opiates, cannabinoids, cocaine, benzodiazepines, tricyclic antidepressants (TCA), 3,4-methylenedioxy-methamphetamine [MDMA; ecstasy]) at screening or D-1.

16. Had a positive alcohol breath test result at screening or D-1. Lifestyle Restrictions 17. Consumed any xanthine-containing products (e.g., coffee, tea, chocolate, or Coca-Cola like drinks) more than 6 cups per day (or equivalent), or alcoholic beverages within 24h before study D1.

18. Had regular consumption of alcoholic beverages that exceeded 21 units per week (1 unit = 12 g of pure alcohol) for males and 14 units per week for females.

19. Consumed nicotine daily (i.e., ≥10 cigarettes, vaping or chewing tobacco, nicotine patch or gum), or was unable to stop, from screening to the end of the hospitalization period or had substantial changes in nicotine consumption in the 4 weeks prior to screening. Prior/Concurrent Clinical Study Experience 20. Participants who had participated in another clinical study and were in the exclusion period or were participating in or intended to participate in another clinical study of an drug before completion of all scheduled evaluations in this clinical study.

Prohibited Treatments 21. Used any prescription drugs within 2 weeks prior to first dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, St. John's wort, dietary supplements) within 5 days prior to first dosing (14 days for compounds with a half-life longer than 24h). Paracetamol (acetaminophen) was acceptable, if allowed by the Investigator, up to 2 intakes of 1000 mg per day. Prescribed hormonal for and HRT for women was also acceptable. Other Exclusions 22. Participants who, in the opinion of the Investigator, were not likely to complete the study for whatever reason.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    ADV7103

    open label single group phase 1

    Drug: ADV7103

Interventions

  • EFFECT ON GASTRIC PH

    Also known as: Sibnayal

06

What researchers measure

Primary outcomes

  1. The effect of a single dose of ADV7103 on gastric pH under fasting and fed conditions in adult healthy participants.

    Time frame: 4 days

07

Study locations

1 site
  • Center Eugène Marquis, Laboratoire de Biologie
    Rennes, 35042, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Mar 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartActual
Feb 25, 2025
Primary completionActual
Mar 15, 2025
CompletionActual
Mar 15, 2025
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07446881
Lead sponsor
Advicenne Pharma
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Feb 25, 2025
Primary completion
Mar 15, 2025
Completion
Mar 15, 2025
Last update
Mar 10, 2026

Study contacts

Adrian J Hapner, MD, PhD
study director · Advicenne S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ADV7103

Start the discussion